|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Inflamation, uvea, adjunct |
|
Mydriasis |
| |
|
|
SIDE EFFECTS:
|
|
Clumsiness or unsteadiness |
|
confusion or unusual behavior |
|
dizziness |
|
dryness of skin |
|
fever |
|
flushing or redness of face |
|
hallucinations |
|
skin rash |
|
slurred speech |
|
swollen stomach in infants |
|
tachycardia |
|
unusual drowsiness |
|
tiredness or weakness |
|
xerostomia |
|
Blurred vision |
|
eye irritation not present before therapy |
|
increased sensitivity of eyes to light |
|
swelling of the eyelids |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Brain damage, in children |
|
Down's syndrome , in children and adults |
|
>> Glaucoma, primary, or predisposition to angle closure |
|
Keratoconus |
|
Sensitivity to atropine |
|
Spastic paralysis, in children |
|
|
ADULT DOSE:
|
|
Uveitis-Topical, to the conjunctiva, 0.3 to 0.5 cm of a l% ointment one or two times a day. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Cycloplegic refraction-Topical, to the conjunctiva, 0.3 cm of the following concentrations three times a day for one to three days prior to refraction:
Children up to 2 years of age with blue irides- 0.5%.
Children up to 2 years of age with dark irides- 1%.
Children 2 years of age and over- 1%.
Uveitis
[Postoperative mydriasis]-Topical, to the conjunctiva, 0.3 to 0.5 cm of a 0.5 or 1% ointment one to three times a day. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|